Inhibrx Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Insider Selling: Inhibrx, Inc (NASDAQ:INBX) Insider Sells 300,000 Shares of Stock

Inhibrx, Inc. (NASDAQ:INBX – Get Free Report) insider Brendan P. Eckelman sold 300,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $34.30, for a total value of $10,290,000.00. Following the sale, the insider now directly owns 1,735,553 shares of the company’s stock, […]

United statesBrendanp eckelmanSecurities exchange commissionChina universal asset management coInhibrx incInhibrx company profileQuadrant capital groupGet free reportExchange commissionCapital groupUniversal asset managementArizona state retirement systemInhibrx daily

Sanofi: Sanofi completes acquisition of Inhibrx, Inc

Sanofi: Sanofi completes acquisition of Inhibrx, Inc
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalCorentine driancourtEvan berlandNathalie phamTarik elgoutniInhibrx biosciencesFelix lauscherThomas kudsk larsenSandrine guendoulInhibrix biosciencesTimothy gilbertInhibrx biosciences incCenterview partnersInhibrx incGotshal mangesKudsk larsen

Press Release: Sanofi completes acquisition of Inhibrx, Inc

Press Release: Sanofi completes acquisition of Inhibrx, Inc
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

France generalEvan berlandInhibrx biosciencesNathalie phamTimothy gilbertTarik elgoutniFelix lauscherSandrine guendoulThomas kudsk larsenCorentine driancourtInhibrix biosciencesInhibrx incCenterview partnersGotshal mangesInhibrx biosciences incNasdaq global market

Inhibrx Inc Stockholders Approve Sale of INBRX-101 to Sanofi

Inhibrx Inc Stockholders Approve Sale of INBRX-101 to Sanofi
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Inhibrx biosciences incExchange commissionInhibrx incSecurities exchangeInhibrx biosciencesCurrent reportNew inhibrxNasdaq global marketSecurities exchange actMiddle eastAnnual reportQuarterly reportsCurrent reportsPrivate securities litigation reform actMedia contact

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Set for Significant Growth

The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is projected to reach USD 2,517 million by 2032, up from USD 1,413 million in 2022, growing at a CAGR of 6.1% during the forecast period from 2022 to 2032. This growth is driven by several key factors, including increasing awareness of AATD.

Costa ricaNew zealandUnited arab emiratesCzech republicSouth koreaUnited kingdomUnited statesRepublic ofSouth africaSaudi arabiaComunidad autonoma de catalunaApic bioZemaira respreezaAsia pacificInhibrx incMereo biopharma group